At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
florbetapir 18F +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.
In Brief
A Phase 2 clinical trial evaluating florbetapir 18F and 18F-FDG for Alzheimer's Disease and Frontotemporal Dementia. Completed, enrolled 34 participants across 1 site.
Detailed Summary
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Frontotemporal Dementia
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
Primary CompletionDec 2012
Study CompletionApr 2013
First PostedJul 2013
TodayJul 2026
First PostedJul 1, 2013
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.0 years ago
Interventions
florbetapir 18Fdrug
Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDGdrug
FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.